ORCID "0000-0003-1864-0316" Fakülteler için listeleme
-
Convalescent plasma therapy in patients with COVID-19
Altuntaş, Fevzi; Ata, Naim; Yigenoğlu, Tuğçe Nur; Başcı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Çelik, Osman; Turgut, Burhan (Pergamon-Elsevier Science Ltd, 2021)Introduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and ... -
Convalescent plasma therapy in patients with COVID-19
Yigenoğlu, Tuğçe Nur; Hacıbekiroğlu, Tuba; Berber, İlhami; Dal, Mehmet Sinan; Baştürk, Abdulkadir; Namdaroğlu, Sinem; Altuntaş, Fevzi; Turgut, Burhan (Wiley, 2020)There are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using ... -
COVID-19 clinical course and blood groups: Turkish population-based study
Dal, Mehmet Sinan; Ata, Naim; Altuntaş, Fevzi; Başcı, Semih; Yigenoğlu, Tuğçe Nur; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Tubitak Scientific & Technical Research Council Turkey, 2021)Background/aim: SARS-CoV-2 enters the cell through the binding of the S glycoprotein on the surface of the virus to the angiotensin-converting enzyme 2 (ACE-2) in the host cells and also SARS-CoV S protein binding to ACE-2 ... -
COVID-19 in hematopoietic cell transplant recipients
Altuntaş, Fevzi; Ata, Naim; Yigenoğlu, Tuğçe Nur; Başcı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Springernature, 2021)In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A ... -
Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
Tombak, Anıl; Pepedil Tanrıkulu, Funda; Durusoy, Salih Sertaç; Dinçyürek, Hüseyin Derya; Kaya, Emin; Ümit, Elif Gülsüm; Ferhanoğlu, Burhan; Akpınar, Seval; Turgut, Burhan (Galenos Yayincilik, 2021)Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients ... -
Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study
Tombak, Anıl; Pepedil Tanrıkulu, Funda; Durusoy, Salih Sertaç; Gürkan, Emel; Kaya, Emin; Ümit, Elif Gülsüm; Ferhanoğlu, Burhan; Akpınar, Seval (Amer Soc Hematology, 2019)[No Abstract Available] -
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors
Başcı, Semih; Ata, Naim; Altuntaş, Fevzi; Yigenoğlu, Tuğçe Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Sage Publications Ltd, 2020)Introduction In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method The data of 16 laboratory-confirmed COVID-19 patients with ... -
The outcome of COVID-19 in patients with hematological malignancy
Yigenoğlu, Tuğçe Nur; Ata, Naim; Altuntaş, Fevzi; Başçı, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Wiley, 2021)In this study, we aim to report the outcomes for COVID-19 in patients with hematological malignancy in Turkey. Data from laboratory-confirmed 188 897 COVID-19 patients diagnosed between 11 March 2020 and 22 June 2020 ... -
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers
Başcı, Semih; Ata, Naim; Altuntaş, Fevzi; Yigenoğlu, Tuğçe Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Birinci, Şuayip; Turgut, Burhan (Springer-Verlag Italia Srl, 2022)Previous studies reported that COVID-19 patients with cancer had higher rates of severe events such as intensive care unit (ICU) admission, mechanical ventilation (MV) assistance, and death during the COVID-19 course ...